Zoppini Giacomo, Targher Giovanni, Venturi Cristina, Zamboni Cristina, Muggeo Michele
Division of Endocrinology and Metabolic Diseases, University of Verona, Verona, Italy.
Clin Endocrinol (Oxf). 2004 Dec;61(6):711-5. doi: 10.1111/j.1365-2265.2004.02154.x.
To examine the association between nonalcoholic hepatic steatosis (HS) and the activity of the hypothalamo-pituitary-adrenal (HPA) axis, as evaluated by a low-dose dexamethasone suppression test, in obese subjects.
In a cross-sectional study, we examined 54 obese, otherwise healthy, individuals with a negligible or zero daily alcohol consumption.
HS (by ultrasonography), glucose tolerance status (by oral glucose load), insulin resistance [by homeostasis model assessment (HOMA)] and 1.0 mg postdexamethasone (postdex) suppression cortisol levels were measured.
Subjects with nonalcoholic HS (n = 39) had markedly less suppressed circulating cortisol levels than those without HS (n = 15) (21.9 +/- 2.6 vs. 11.0 +/- 1.4 nmol/l, P < 0.001). In addition, subjects with nonalcoholic HS had significantly higher values of HOMA-insulin resistance score and circulating liver enzymes than their counterparts without HS. Age, body mass index (BMI), waist/hip ratio, plasma glucose concentration (both at fasting and after glucose load), lipids and blood pressure values did not differ significantly between the groups. Females were more represented among those without HS. The marked differences in postdex suppression cortisol levels that were observed between the groups were little affected by adjustment for sex, age, BMI, waist/hip ratio, HOMA-insulin resistance score, plasma lipids and liver enzyme levels. Similarly, in a logistic regression analysis, cortisol levels significantly predicted the presence of nonalcoholic HS (P = 0.032), independently of potential confounders.
These results suggest that nonalcoholic hepatic steatosis is closely correlated with a subtle, chronic activation of the HPA axis in obese, otherwise healthy, individuals.
通过低剂量地塞米松抑制试验评估肥胖受试者中非酒精性肝脂肪变性(HS)与下丘脑 - 垂体 - 肾上腺(HPA)轴活性之间的关联。
在一项横断面研究中,我们检查了54名肥胖但其他方面健康且每日酒精摄入量可忽略不计或为零的个体。
测量HS(通过超声检查)、糖耐量状态(通过口服葡萄糖负荷试验)、胰岛素抵抗[通过稳态模型评估(HOMA)]以及地塞米松给药后(postdex)1.0 mg抑制后的皮质醇水平。
非酒精性HS患者(n = 39)的循环皮质醇水平抑制程度明显低于无HS患者(n = 15)(21.9±2.6 vs. 11.0±1.4 nmol/l,P < 0.001)。此外,非酒精性HS患者的HOMA - 胰岛素抵抗评分和循环肝酶值显著高于无HS的对应患者。两组之间的年龄、体重指数(BMI)、腰臀比、血浆葡萄糖浓度(空腹和葡萄糖负荷后)、血脂和血压值无显著差异。无HS的人群中女性比例更高。两组之间观察到的postdex抑制皮质醇水平的显著差异在对性别、年龄、BMI、腰臀比、HOMA - 胰岛素抵抗评分、血浆脂质和肝酶水平进行调整后受影响较小。同样,在逻辑回归分析中,皮质醇水平显著预测了非酒精性HS的存在(P = 0.032),独立于潜在混杂因素。
这些结果表明,在肥胖但其他方面健康的个体中,非酒精性肝脂肪变性与HPA轴的轻微慢性激活密切相关。